Your browser doesn't support javascript.
loading
Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé, Jaume; Fernández-Galán, Esther; Auge, Josep Maria; Carbonell-Prat, Marina; Filella, Xavier; Miró-Cañís, Sílvia; González-Fernández, Carolina.
Afiliación
  • Trapé J; Department of Laboratory Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Fernández-Galán E; Tissue Repair and Regeneration Laboratory, Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central, Barcelona, Spain.
  • Auge JM; Faculty of Medicine, University of Vic - Central University of Catalonia, Vic, Spain.
  • Carbonell-Prat M; Department of Biochemistry and Molecular Genetics - Hospital Clinic de Barcelona, Barcelona, Spain.
  • Filella X; Department of Biochemistry and Molecular Genetics - Hospital Clinic de Barcelona, Barcelona, Spain.
  • Miró-Cañís S; Laboratori d'Anàlisis Clíniques, CLILAB Diagnòstics, Vilafranca del Penedès, Spain.
  • González-Fernández C; Department of Biochemistry and Molecular Genetics - Hospital Clinic de Barcelona, Barcelona, Spain.
Tumour Biol ; 46(s1): S35-S63, 2024.
Article en En | MEDLINE | ID: mdl-38517826
ABSTRACT

BACKGROUND:

Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce the synthesis of TMs, and the release of these molecules into the bloodstream allows their quantification in biological fluids. Although very small concentrations of TMs are usually present in the serum or plasma of healthy subjects, increased concentrations may also be found in the presence of benign diseases or due to technical interference, producing false positive results. MATERIAL AND METHODS AND

RESULTS:

Our review analyses the causes of false positives described between January 1970 to February 2023 for the TMs most frequently used in clinical practice α-fetoprotein (AFP), ß2-microglobulin (ß2-M), cancer antigen 15-3 (CA 15-3), cancer antigen CA 19-9 (CA 19-9), cancer antigen CA 72-4 (CA 72-4), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), chromogranin A (CgA), choriogonadotropin (hCG), cytokeratin 19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), human epididymis protein 4 (HE4), serum HER2 (sHER2), squamous cell carcinoma antigen (SCCA), protein induced by vitamin K absence-II (PIVKA-II), Pro-gastrin-releasing peptide (Pro-GRP), prostate-specific antigen (PSA), Protein S-100 (S-100) and thyroglobulin (Tg). A total of 247 references were included.

CONCLUSIONS:

A better understanding of pathophysiological processes and other conditions that affect the concentration of TMs might improve the interpretation of results and their clinical application.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Neoplasias Pulmonares Límite: Humans / Male Idioma: En Revista: Tumour Biol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Neoplasias Pulmonares Límite: Humans / Male Idioma: En Revista: Tumour Biol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos